Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Naltrexone (LDN) Immune Monitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females age 18-65~* Meets criteria for 1990 ACR criteria for fibromyalgia~* Able to receive venous blood draw twice a week for 16 weeks~* Sufficient symptom variability during baseline report~* Patient completes daily report during 2 week baseline period at least 80% completion rate.~Exclusion Criteria:~* Opioid use~* Significant psychological comorbidity that in the discretion of the investigator compromises study integrity~* Location prohibits travel to Stanford~* Blood or clotting disorder~* Rheumatologic or autoimmune disease~* Acute infection~* Baseline blood ESR \>60, CRP greater than 3.0mg/L, positive rheumatoid factor, or positive ANA~* Use of blood thinning medication~* Pregnant or currently planning to become pregnant~* Current use of aspirin, ibuprofen, naproxen, or other confounding-anti-inflammatory medication as part of regular medication regimen.~* Known allergy to Naltrexone or Naloxone~* Currently participating in another treatment-based research study~* Self-reported inability to refrain from alcohol for the duration of the study period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Naltrexone (LDN) (Type: OTHER): Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.

Based on this trial design, predict the completion outcome and termination type (if applicable).